Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy

Cancer Letters

Volumn 235, Issue 2, 2006, Pages 298-308

  Marty, Cornelia ^a   Langer Machova, Zuzana ^a   Sigrist, Sandra ^a   Schott, Herbert ^b   Schwendener, Reto A ^a   Ballmer Hofer, Kurt ^a  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Angiogenesis; Endosialin; Liposomes; scFv; TEM1; Tumor endothelial marker 1

Indexed keywords

CYTIDINE DERIVATIVE; IMMUNOLIPOSOME; LIPOSOME; REAGENT; TUMOR MARKER;

ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER THERAPY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL; WESTERN BLOTTING;

ANTIBODY SPECIFICITY; CELL LINE; CYTARABINE; CYTIDINE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LIPOSOMES; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDE LIBRARY; RECOMBINANT PROTEINS;

EID: 33646062270     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.04.029     Document Type: Article

References (29)

1. Folkman J. Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3 (2003) 643-651
2. Rettig W.J., Garin-Chesa P., Healey J.H., Su S.L., Jaffe E.A., and Old L.J. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc. Natl. Acad. Sci. USA 89 (1992) 10832-10836
3. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., et al. Genes expressed in human tumor endothelium. Science 289 (2000) 1197-1202
4. Nanda A., and St Croix B. Tumor endothelial markers: new targets for cancer therapy. Curr. Opin. Oncol. 16 (2004) 44-49
5. Opavsky R., Haviernik P., Jurkovicova D., Garin M.T., Copeland N.G., Gilbert D.J., et al. Molecular characterization of the mouse Tem1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo. J. Biol. Chem. Oct. 276 (2001) 38795-38807
6. Davies G., Cunnick G.H., Mansel R.E., Mason M.D., and Jiang W.G. Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin. Exp. Met. 21 (2004) 31-37
7. Brady J., Neal J., Sadakar N., and Gasque P. Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J. Neuropathol. Exp. Neurol. 63 (2004) 1274-1283
8. Christian S., Ahorn H., Koehler A., Eisenhaber F., Rodi H.P., Garin-Chesa P., et al. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J. Biol. Chem. 276 (2001) 7408-7414
9. Pini A., Viti F., Santucci A., Carnemolla B., Zardi L., Neri P., and Neri D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 273 (1998) 21769-21776
10. Griffiths A.D., and Duncan A.R. Strategies for selection of antibodies by phage display. Curr. Opin. Biotechnol. 9 (1998) 102-108
11. Weisbart R.H., Miller C.W., Chan G., Wakelin R., Ferreri K., and Koeffler H.P. Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells. Cancer Lett. 195 (2003) 211-219
12. Haubner R., and Wester H.J. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr. Pharm. Des. 10 (2004) 1439-1455
13. Cheng T.L., Liao K.W., Tzou S.C., Cheng C.M., Chen B.M., and Roffler S.R. Hapten-directed targeting to single-chain antibody receptors. Cancer Gene Ther. 11 (2004) 380-388
14. Onda M., Wang Q.C., Guo H.F., Cheung N.K., and Pastan I. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res. 64 (2004) 1419-1424
15. Marty C., Scheidegger P., Ballmer-Hofer K., Klemenz R., and Schwendener R.A. Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris. Protein Expr. Pur. 21 (2001) 156-164
16. Sundaresan G., Yazaki P.J., Shively J.E., Finn R.D., Larson S.M., Raubitschek A.A., et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J. Nucl. Med. 44 (2003) 1962-1969
17. Marty C., Odermatt B., Schott H., Neri D., Ballmer-Hofer K., Klemenz R., and Schwendener R.A. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br. J. Cancer 87 (2002) 106-112
18. Schwendener R.A., Trub T., Schott H., Langhals H., Barth R.F., Groscurth P., and Hengartner H. Comparative studies of the preparation of immunoliposomes with the use of two bifunctional coupling agents and investigation of in vitro immunoliposome-target cell binding by cytofluorometry and electron microscopy. Biochim. Biophys. Acta 1026 (1990) 69-79
19. Cattaneo-Pangrazzi R.M., Schott H., and Schwendener R.A. The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145. Prostate 45 (2000) 8-18
20. Takatori S., Kanda H., Takenaka K., Wataya Y., Matsuda A., Fukushima M., et al. Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)uracil. Cancer Chemother. Pharmacol. 44 (1999) 97-104
21. Geiser M., Cebe R., Drewello D., and Schmitz R. Integration of PCR fragments at any specific site within cloning vectors without the use of restriction enzymes and DNA ligase. Biotechniques 31 (2001) 88-90 (see also page 92)
22. Rubio Demirovic A., Marty C., Console S., Zeisberger S.M., Ruch C., Jaussi R., et al. Targeting human cancer cells with VEGF receptor-2-directed liposomes. Oncol. Rep. 13 (2005) 319-324
23. Marty C., Meylan C., Schott H., Ballmer-Hofer K., and Schwendener R.A. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell Mol. Life Sci. 61 (2004) 1785-1794
24. Matsuno F., Haruta Y., Kondo M., Tsai H., Barcos M., and Seon B.K. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin. Cancer Res. 5 (1999) 371-382
25. Keyes K.A., Mann L., Sherman M., Galbreath E., Schirtzinger L., Ballard D., et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother. Pharmacol. 53 (2004) 133-140
26. Ebbinghaus C., Scheuermann J., Neri D., and Elia G. Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr. Pharm. Des 10 (2004) 1537-1549
27. Fox S.B., and Harris A.L. Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Invest. New Drugs 15 (1997) 15-28
28. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., and Baselga J. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8 (2002) 1172-1181
29. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63 (2003) 7400-7409